This article was originally published in The Tan Sheet
Store-brand phenylephrine products from Leiner will begin shipping in June to fill the gap on retail shelves left by pseudoephedrine, the private labeler announced April 22. The announcement follows Target's decision to place pseudoephedrine behind pharmacy counters. Phenylephrine is an active ingredient in Bayer's Alka-Seltzer Plus and compared to pseudoephedrine, "has fewer side effects and...does not interfere with sleep," Leiner claims. The firm's products will compete with Pfizer's Sudafed PE phenylephrine, launched in January, and other private-label offerings...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”